caa a22 4500 465735630 CHVBK 20180323111754.0 cr unu---uuuuu 170327e19900601xx s 000 0 eng 10.1007/BF00177355 doi (NATIONALLICENCE)springer-10.1007/BF00177355 Radioimaging of human glioma xenografts with 123I labeled monoclonal antibody G-22 against glioma-associated antigen [Elektronische Daten] [Jun Yoshida, Masaaki Mizuno, Itaru Inoue, Toshihiko Wakabayasi, Kenichiro Sugita, Hisao Seo, Kazumi Chiba] Summary: Monoclonal antibody (MCA) G-22 is directed against a human glioma-associated surface antigen. Its availability for the radioimmunodetection of human glioma was analyzed by utilizing the xenografts in athymic mice. Nude mice with subcutaneous grafts of U251-MG or U251-SP glioma received intravenous administration of 123I or 131I labeled F(ab′)2 fragment or whole immunoglobulin. Results of radioimaging revealed that 123I-labeled antibody was better than the 131I-labeled. It was also noted that administration of 123I-labeled F(ab′)2 fragment of G-22 MCA enabled the imaging of human glioma xenografts weighing 80-650 mg after 48 hours. When biodistribution of 123I MCA was compared between G-22 and control antibodies, the percentages of dose/g in tumors were 5.228-1.799 at 30 hours and 4.112-1.132 at 48 hours with G-22 and they were 4.164-1.248 and 0.314-0.142 with control. The tumor/blood ratio until 72 hours after injection was constantly above 1 with G-22 and less than 1 with control antibody. These results indicate the potential usefulness of G-22 MCA for the radioimmunodetection of human gliomas. Kluwer Academic Publishers, 1990 radioimaging nationallicence monoclonal antibody nationallicence glioma nationallicence glioma-associated antigen nationallicence 123I nationallicence Yoshida Jun Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan aut Mizuno Masaaki Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan aut Inoue Itaru Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan aut Wakabayasi Toshihiko Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan aut Sugita Kenichiro Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan aut Seo Hisao Department of Endocrinology and Metabolism, Research Institute of Environmental Medicine, Nagoya, Japan aut Chiba Kazumi LTD, Daiichi Radioisotope Laboratories, Chiba, Japan aut Journal of Neuro-Oncology Kluwer Academic Publishers 8/3(1990-06-01), 221-229 0167-594X 8:3<221 1990 8 11060 https://doi.org/10.1007/BF00177355 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00177355 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yoshida Jun Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan aut NATIONALLICENCE 700 1- Mizuno Masaaki Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan aut NATIONALLICENCE 700 1- Inoue Itaru Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan aut NATIONALLICENCE 700 1- Wakabayasi Toshihiko Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan aut NATIONALLICENCE 700 1- Sugita Kenichiro Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan aut NATIONALLICENCE 700 1- Seo Hisao Department of Endocrinology and Metabolism, Research Institute of Environmental Medicine, Nagoya, Japan aut NATIONALLICENCE 700 1- Chiba Kazumi LTD, Daiichi Radioisotope Laboratories, Chiba, Japan aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 8/3(1990-06-01), 221-229 0167-594X 8:3<221 1990 8 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer